Literature DB >> 1642079

C-peptide profiles in patients with non-insulin-dependent diabetes mellitus before and during insulin treatment.

T Lindström1, H J Arnqvist, J Ludvigsson, H H von Schenck.   

Abstract

The objective of the study was to evaluate the effect of insulin treatment on insulin secretion in patients with non-insulin-dependent diabetes mellitus (NIDDM). Ten patients with NIDDM were first investigated while still taking oral hypoglycemic agents, and then randomized to a crossover study with two eight-week periods of insulin treatment (oral treatment having been stopped) given either as mainly intermediate-acting insulin twice daily (2-dose) or as preprandial regular insulin and intermediate-acting insulin at bedtime (4-dose). In the patients treated with oral agents the 24-h C-peptide area under the curve was similar to that in the controls, but the profile was different with a rise at breakfast but with almost absent meal peaks during the rest of the day. Insulin treatment improved glycemic control markedly, lowered urinary C-peptide excretion and the serum C-peptide concentrations being reduced by more than 50%. The shape of the C-peptide profiles was unaltered and there were no significant differences between the two insulin regimens. The decrease in serum C-peptide concentration during insulin treatment correlated with the change in blood glucose. Fasting serum C-peptide concentrations correlated closely with the 24-h C-peptide area under the curve. In conclusion, insulin treatment of NIDDM patients with secondary failure to oral agents greatly reduces the insulin secretion, probably owing to the reduction in blood glucose.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1642079     DOI: 10.1530/acta.0.1260477

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  5 in total

Review 1.  Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus.

Authors:  A N Goudswaard; N J Furlong; G E H M Rutten; R P Stolk; G D Valk
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18

Review 2.  The clinical utility of C-peptide measurement in the care of patients with diabetes.

Authors:  A G Jones; A T Hattersley
Journal:  Diabet Med       Date:  2013-07       Impact factor: 4.359

3.  Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β-cell function.

Authors:  Ryota Usui; Daisuke Yabe; Hitoshi Kuwata; Shuichi Fujiwara; Koin Watanabe; Takanori Hyo; Akihiro Yasuhara; Masahiro Iwasaki; Naomi Kitatani; Kyoko Kuwabara; Kayo Yokota; Takeshi Kurose; Yutaka Seino
Journal:  J Diabetes Investig       Date:  2013-06-25       Impact factor: 4.232

4.  Practical Classification Guidelines for Diabetes in patients treated with insulin: a cross-sectional study of the accuracy of diabetes diagnosis.

Authors:  Suzy V Hope; Sophie Wienand-Barnett; Maggie Shepherd; Sophie M King; Charles Fox; Kamlesh Khunti; Richard A Oram; Bea A Knight; Andrew T Hattersley; Angus G Jones; Beverley M Shields
Journal:  Br J Gen Pract       Date:  2016-04-14       Impact factor: 5.386

5.  Low fasting glucose-to-estimated average glucose ratio was associated with superior response to insulin degludec/aspart compared with basal insulin in patients with type 2 diabetes.

Authors:  Han Na Jang; Ye Seul Yang; Tae Jung Oh; Bo Kyung Koo; Seong Ok Lee; Kyong Soo Park; Hak Chul Jang; Hye Seung Jung
Journal:  J Diabetes Investig       Date:  2021-08-24       Impact factor: 4.232

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.